Therapeutic Advances in Endocrinology and Metabolism

Papers
(The H4-Index of Therapeutic Advances in Endocrinology and Metabolism is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
GLP-1 receptor agonists: an updated review of head-to-head clinical studies116
Should metformin remain the first-line therapy for treatment of type 2 diabetes?55
Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis33
MAFLD: a multisystem disease31
The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence27
Role of inflammation in diabetic cardiomyopathy25
Testosterone target therapy: focus on immune response, controversies and clinical implications in patients with COVID-19 infection23
Cardiovascular risk in menopausal women and our evolving understanding of menopausal hormone therapy: risks, benefits, and current guidelines for use23
Insulin resistance in transgender individuals correlates with android fat mass20
Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data19
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence?18
Advancements in the treatment of differentiated thyroid cancer17
Diabetes clinic reinvented: will technology change the future of diabetes care?16
The importance of physical activity in management of type 2 diabetes and COVID-1916
Clinical approaches to treat impaired awareness of hypoglycaemia16
NAFLD in type 1 diabetes: overrated or underappreciated?15
0.019913911819458